 Doreen Brettler
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 49 | 2014 | 53 | 3.520 |
Why?
| | Factor VIII | 23 | 2014 | 29 | 1.600 |
Why?
| | HIV Seropositivity | 17 | 1995 | 73 | 0.700 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2015 | 8 | 0.670 |
Why?
| | Acquired Immunodeficiency Syndrome | 11 | 1996 | 125 | 0.510 |
Why?
| | Blood Coagulation Factors | 4 | 1996 | 14 | 0.460 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 34 | 0.410 |
Why?
| | Hodgkin Disease | 1 | 2008 | 46 | 0.410 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2008 | 177 | 0.380 |
Why?
| | HIV | 6 | 1998 | 57 | 0.320 |
Why?
| | Isoantibodies | 2 | 1996 | 26 | 0.320 |
Why?
| | Humans | 66 | 2015 | 34159 | 0.320 |
Why?
| | Hepatitis C | 6 | 1995 | 102 | 0.310 |
Why?
| | Leukocyte Count | 8 | 2015 | 81 | 0.290 |
Why?
| | HIV-1 | 8 | 1999 | 571 | 0.290 |
Why?
| | Male | 36 | 2015 | 17242 | 0.270 |
Why?
| | HIV Infections | 10 | 1999 | 655 | 0.270 |
Why?
| | Sexual Behavior | 2 | 1992 | 141 | 0.250 |
Why?
| | Blood Transfusion | 7 | 1992 | 124 | 0.220 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 477 | 0.220 |
Why?
| | Surgical Procedures, Operative | 2 | 1996 | 78 | 0.210 |
Why?
| | Immunoglobulin G | 3 | 2014 | 337 | 0.210 |
Why?
| | Home Infusion Therapy | 2 | 2001 | 6 | 0.200 |
Why?
| | Child | 19 | 2001 | 2648 | 0.200 |
Why?
| | Hemorrhage | 3 | 2001 | 162 | 0.200 |
Why?
| | Professional Staff Committees | 1 | 1997 | 5 | 0.190 |
Why?
| | Child, Preschool | 13 | 2001 | 1311 | 0.190 |
Why?
| | Clinical Trials as Topic | 3 | 1997 | 309 | 0.190 |
Why?
| | Malaria Vaccines | 1 | 1997 | 19 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 1997 | 54 | 0.190 |
Why?
| | HIV Antibodies | 4 | 1994 | 117 | 0.190 |
Why?
| | Adult | 28 | 2001 | 9698 | 0.190 |
Why?
| | Factor IX | 5 | 2000 | 10 | 0.180 |
Why?
| | Hemostasis | 1 | 1996 | 15 | 0.180 |
Why?
| | Anterior Cruciate Ligament | 1 | 1995 | 10 | 0.170 |
Why?
| | Diverticulitis | 1 | 2015 | 13 | 0.170 |
Why?
| | Autoantibodies | 2 | 2014 | 117 | 0.170 |
Why?
| | Zidovudine | 2 | 1994 | 15 | 0.170 |
Why?
| | Cysts | 1 | 1995 | 31 | 0.170 |
Why?
| | Fluorescence Polarization Immunoassay | 1 | 2014 | 3 | 0.160 |
Why?
| | Arthroplasty | 1 | 1994 | 3 | 0.160 |
Why?
| | Menisci, Tibial | 1 | 1994 | 9 | 0.160 |
Why?
| | Hepatitis Antibodies | 3 | 1992 | 6 | 0.160 |
Why?
| | Sexual Partners | 3 | 1991 | 70 | 0.160 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 86 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-ets | 2 | 2011 | 18 | 0.150 |
Why?
| | Knee Joint | 3 | 1995 | 66 | 0.150 |
Why?
| | Adolescent | 16 | 2014 | 4025 | 0.150 |
Why?
| | T-Lymphocytes, Cytotoxic | 6 | 1999 | 166 | 0.150 |
Why?
| | Hepatitis, Viral, Human | 2 | 1990 | 8 | 0.150 |
Why?
| | Hemophilia B | 3 | 1996 | 6 | 0.150 |
Why?
| | Immune Tolerance | 3 | 1993 | 140 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2015 | 2864 | 0.140 |
Why?
| | Immunophenotyping | 3 | 2009 | 167 | 0.140 |
Why?
| | Comprehensive Health Care | 1 | 1993 | 19 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 1 | 1994 | 229 | 0.130 |
Why?
| | Repressor Proteins | 2 | 2011 | 274 | 0.130 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 9 | 0.130 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 20 | 0.130 |
Why?
| | Postoperative Complications | 1 | 1995 | 603 | 0.120 |
Why?
| | Hypersensitivity, Delayed | 3 | 1987 | 27 | 0.120 |
Why?
| | Aged | 11 | 2008 | 7641 | 0.120 |
Why?
| | Growth Disorders | 1 | 1990 | 41 | 0.120 |
Why?
| | Antigens | 2 | 1996 | 160 | 0.110 |
Why?
| | Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 4 | 0.110 |
Why?
| | Basophils | 1 | 2009 | 12 | 0.110 |
Why?
| | Middle Aged | 16 | 2011 | 9874 | 0.110 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.110 |
Why?
| | Antibodies | 1 | 1989 | 151 | 0.100 |
Why?
| | Family Planning Services | 1 | 1988 | 15 | 0.100 |
Why?
| | Immune System | 1 | 1989 | 98 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2008 | 185 | 0.100 |
Why?
| | Antibodies, Monoclonal | 3 | 1992 | 685 | 0.100 |
Why?
| | Infant | 7 | 2001 | 951 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 1992 | 402 | 0.090 |
Why?
| | Hemarthrosis | 1 | 1985 | 3 | 0.080 |
Why?
| | Antibody Formation | 3 | 2000 | 103 | 0.080 |
Why?
| | Joint Diseases | 1 | 1985 | 19 | 0.080 |
Why?
| | HIV Seronegativity | 2 | 1994 | 18 | 0.080 |
Why?
| | Genes, nef | 2 | 1995 | 6 | 0.080 |
Why?
| | Recombinant Proteins | 6 | 2000 | 612 | 0.080 |
Why?
| | Risk Factors | 6 | 2001 | 3030 | 0.070 |
Why?
| | Polymerase Chain Reaction | 5 | 1999 | 452 | 0.070 |
Why?
| | Prospective Studies | 7 | 1996 | 1668 | 0.070 |
Why?
| | Age Factors | 1 | 2005 | 1100 | 0.060 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 1991 | 100 | 0.060 |
Why?
| | Multicenter Studies as Topic | 3 | 1991 | 50 | 0.060 |
Why?
| | Female | 10 | 2011 | 18881 | 0.060 |
Why?
| | Antibodies, Viral | 4 | 1987 | 224 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 1994 | 1543 | 0.060 |
Why?
| | Risk Assessment | 1 | 2005 | 1081 | 0.060 |
Why?
| | Cohort Studies | 5 | 2001 | 1417 | 0.060 |
Why?
| | HIV Long-Term Survivors | 1 | 1999 | 8 | 0.060 |
Why?
| | Time Factors | 3 | 2014 | 2605 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2005 | 2667 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 1979 | 19 | 0.050 |
Why?
| | DNA, Viral | 3 | 1995 | 192 | 0.050 |
Why?
| | Gene Products, gag | 3 | 1997 | 56 | 0.050 |
Why?
| | Hypohidrosis | 1 | 1998 | 2 | 0.050 |
Why?
| | Semen | 1 | 1998 | 9 | 0.050 |
Why?
| | Sjogren's Syndrome | 1 | 1998 | 12 | 0.050 |
Why?
| | Sweat Gland Neoplasms | 1 | 1998 | 12 | 0.050 |
Why?
| | Alopecia | 1 | 1998 | 15 | 0.050 |
Why?
| | Lymphoma, T-Cell | 1 | 1998 | 22 | 0.050 |
Why?
| | Pruritus | 1 | 1998 | 19 | 0.050 |
Why?
| | Fractures, Bone | 1 | 1979 | 115 | 0.050 |
Why?
| | Leukocytes | 1 | 1998 | 107 | 0.050 |
Why?
| | T-Lymphocytes | 3 | 1999 | 898 | 0.050 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1996 | 6 | 0.050 |
Why?
| | Hospitalization | 1 | 2001 | 637 | 0.050 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1996 | 32 | 0.040 |
Why?
| | Desensitization, Immunologic | 1 | 1996 | 6 | 0.040 |
Why?
| | Anaphylaxis | 1 | 1996 | 22 | 0.040 |
Why?
| | Immunization | 1 | 1996 | 118 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 1994 | 523 | 0.040 |
Why?
| | Martial Arts | 1 | 1995 | 1 | 0.040 |
Why?
| | Patella | 1 | 1995 | 5 | 0.040 |
Why?
| | Pregnancy | 2 | 1991 | 1207 | 0.040 |
Why?
| | Factor VII | 2 | 1992 | 4 | 0.040 |
Why?
| | Species Specificity | 1 | 1996 | 298 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 1995 | 55 | 0.040 |
Why?
| | Tendons | 1 | 1995 | 16 | 0.040 |
Why?
| | Bone Transplantation | 1 | 1995 | 23 | 0.040 |
Why?
| | Knee Injuries | 1 | 1995 | 19 | 0.040 |
Why?
| | Tibia | 1 | 1995 | 30 | 0.040 |
Why?
| | Patient Selection | 1 | 1997 | 309 | 0.040 |
Why?
| | Swine | 1 | 1996 | 328 | 0.040 |
Why?
| | Bone Resorption | 1 | 1995 | 44 | 0.040 |
Why?
| | HIV Core Protein p24 | 2 | 1991 | 22 | 0.040 |
Why?
| | HIV Antigens | 2 | 1991 | 22 | 0.040 |
Why?
| | Reference Values | 2 | 1992 | 305 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1994 | 11 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 1998 | 231 | 0.040 |
Why?
| | Arthroscopy | 1 | 1994 | 22 | 0.040 |
Why?
| | von Willebrand Diseases | 2 | 1992 | 3 | 0.040 |
Why?
| | Radiography | 1 | 1995 | 311 | 0.040 |
Why?
| | Osteotomy | 1 | 1994 | 12 | 0.040 |
Why?
| | Blotting, Western | 2 | 1992 | 538 | 0.040 |
Why?
| | Terminology as Topic | 1 | 1994 | 103 | 0.040 |
Why?
| | Prevalence | 3 | 1992 | 795 | 0.040 |
Why?
| | Gene Deletion | 1 | 1995 | 234 | 0.040 |
Why?
| | Hepatitis B | 3 | 1992 | 23 | 0.040 |
Why?
| | Blood Donors | 2 | 1990 | 19 | 0.040 |
Why?
| | Drug Contamination | 2 | 1990 | 11 | 0.040 |
Why?
| | Lymphocyte Activation | 3 | 1999 | 686 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 108 | 0.030 |
Why?
| | Gene Products, nef | 1 | 1992 | 11 | 0.030 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 1 | 1992 | 13 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 1992 | 39 | 0.030 |
Why?
| | Antigens, CD4 | 2 | 1991 | 123 | 0.030 |
Why?
| | Prenatal Diagnosis | 2 | 1992 | 22 | 0.030 |
Why?
| | Factor VIIIa | 1 | 1992 | 1 | 0.030 |
Why?
| | Factor X | 1 | 1992 | 3 | 0.030 |
Why?
| | Factor IXa | 1 | 1992 | 2 | 0.030 |
Why?
| | Prothrombin | 1 | 1992 | 6 | 0.030 |
Why?
| | Factor VII Deficiency | 1 | 1992 | 3 | 0.030 |
Why?
| | Factor VIIa | 1 | 1992 | 3 | 0.030 |
Why?
| | Skin Tests | 3 | 1986 | 15 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 697 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1992 | 35 | 0.030 |
Why?
| | AIDS-Related Complex | 1 | 1991 | 4 | 0.030 |
Why?
| | Prognosis | 1 | 2014 | 937 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 1987 | 123 | 0.030 |
Why?
| | Placebos | 1 | 1991 | 66 | 0.030 |
Why?
| | Herpesviridae Infections | 3 | 1986 | 31 | 0.030 |
Why?
| | Benzamides | 1 | 2011 | 44 | 0.030 |
Why?
| | Pyrimidines | 1 | 2011 | 76 | 0.030 |
Why?
| | HTLV-I Antibodies | 1 | 1990 | 3 | 0.030 |
Why?
| | Immunologic Techniques | 1 | 1990 | 13 | 0.030 |
Why?
| | Pedigree | 1 | 1991 | 159 | 0.030 |
Why?
| | Virus Diseases | 1 | 1992 | 107 | 0.030 |
Why?
| | Virus Replication | 3 | 1999 | 242 | 0.030 |
Why?
| | Growth | 1 | 1990 | 36 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 1991 | 111 | 0.030 |
Why?
| | Piperazines | 1 | 2011 | 103 | 0.030 |
Why?
| | Risk | 2 | 1988 | 346 | 0.030 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 97 | 0.030 |
Why?
| | Viral Proteins | 1 | 1991 | 243 | 0.030 |
Why?
| | Immunity, Cellular | 2 | 1989 | 175 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2009 | 6 | 0.030 |
Why?
| | Chromosomes, Human, Pair 12 | 1 | 2009 | 7 | 0.030 |
Why?
| | Herpesvirus 4, Human | 3 | 1986 | 130 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2009 | 29 | 0.030 |
Why?
| | Half-Life | 1 | 1989 | 55 | 0.030 |
Why?
| | Antigen-Antibody Complex | 1 | 1989 | 50 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 1991 | 182 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 2009 | 53 | 0.030 |
Why?
| | Clinical Protocols | 1 | 1989 | 88 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 118 | 0.030 |
Why?
| | Immunoglobulin E | 1 | 1989 | 95 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 2 | 1999 | 85 | 0.030 |
Why?
| | Antigens, CD8 | 3 | 1994 | 54 | 0.030 |
Why?
| | Deltaretrovirus | 2 | 1986 | 3 | 0.030 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1989 | 100 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2009 | 214 | 0.030 |
Why?
| | New England | 1 | 1988 | 193 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 1988 | 43 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 339 | 0.020 |
Why?
| | Young Adult | 1 | 2014 | 2167 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1988 | 228 | 0.020 |
Why?
| | Dermatitis, Contact | 1 | 1987 | 8 | 0.020 |
Why?
| | Cytomegalovirus | 2 | 1986 | 66 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 615 | 0.020 |
Why?
| | Animals | 2 | 1996 | 14702 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 1988 | 570 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2009 | 494 | 0.020 |
Why?
| | Hepatitis B Antigens | 1 | 1985 | 6 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1987 | 693 | 0.020 |
Why?
| | Motion | 1 | 1985 | 32 | 0.020 |
Why?
| | Long-Term Care | 1 | 1985 | 113 | 0.020 |
Why?
| | United States | 2 | 1990 | 4021 | 0.020 |
Why?
| | Developing Countries | 2 | 1995 | 47 | 0.020 |
Why?
| | Cytomegalovirus Infections | 3 | 1992 | 51 | 0.020 |
Why?
| | World Health Organization | 2 | 1995 | 23 | 0.020 |
Why?
| | Virus Cultivation | 2 | 1994 | 18 | 0.020 |
Why?
| | Receptors, Drug | 1 | 1982 | 4 | 0.020 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 1982 | 20 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1998 | 2049 | 0.020 |
Why?
| | Protein Kinase C | 1 | 1982 | 104 | 0.020 |
Why?
| | Antigens, Viral | 3 | 1987 | 133 | 0.020 |
Why?
| | Neutrophils | 1 | 1982 | 265 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1991 | 38 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 1985 | 398 | 0.010 |
Why?
| | Population Surveillance | 1 | 2001 | 180 | 0.010 |
Why?
| | Receptors, Chemokine | 1 | 1999 | 36 | 0.010 |
Why?
| | Chemokines | 1 | 1999 | 63 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 1982 | 249 | 0.010 |
Why?
| | Viral Load | 1 | 1999 | 169 | 0.010 |
Why?
| | Extremities | 1 | 1979 | 36 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1999 | 168 | 0.010 |
Why?
| | Disease Reservoirs | 1 | 1998 | 6 | 0.010 |
Why?
| | Mice | 1 | 1989 | 7378 | 0.010 |
Why?
| | HIV Protease Inhibitors | 1 | 1998 | 76 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 196 | 0.010 |
Why?
| | Phylogeny | 1 | 1998 | 239 | 0.010 |
Why?
| | HIV Protease | 1 | 1998 | 87 | 0.010 |
Why?
| | Genetic Variation | 1 | 1998 | 255 | 0.010 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 64 | 0.010 |
Why?
| | Developed Countries | 1 | 1995 | 8 | 0.010 |
Why?
| | Consumer Product Safety | 1 | 1995 | 14 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 1491 | 0.010 |
Why?
| | Viremia | 1 | 1994 | 37 | 0.010 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1994 | 19 | 0.010 |
Why?
| | beta 2-Microglobulin | 1 | 1994 | 53 | 0.010 |
Why?
| | Primary Prevention | 1 | 1995 | 93 | 0.010 |
Why?
| | Genes, gag | 1 | 1993 | 11 | 0.010 |
Why?
| | Formaldehyde | 1 | 1993 | 27 | 0.010 |
Why?
| | Histological Techniques | 1 | 1993 | 19 | 0.010 |
Why?
| | Disease Progression | 1 | 1995 | 479 | 0.010 |
Why?
| | Safety | 1 | 1993 | 117 | 0.010 |
Why?
| | Heterozygote Detection | 1 | 1992 | 16 | 0.010 |
Why?
| | Fetal Diseases | 1 | 1992 | 16 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1992 | 12 | 0.010 |
Why?
| | Base Sequence | 1 | 1995 | 1244 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 1991 | 27 | 0.010 |
Why?
| | International Cooperation | 1 | 1992 | 57 | 0.010 |
Why?
| | Hot Temperature | 1 | 1992 | 91 | 0.010 |
Why?
| | Protein Precursors | 1 | 1991 | 67 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 1991 | 49 | 0.010 |
Why?
| | Viral Core Proteins | 1 | 1991 | 34 | 0.010 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 1991 | 36 | 0.010 |
Why?
| | Phenotype | 1 | 1994 | 803 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1991 | 155 | 0.010 |
Why?
| | Hemostasis, Surgical | 1 | 1990 | 7 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1990 | 39 | 0.010 |
Why?
| | France | 1 | 1990 | 10 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1990 | 5 | 0.010 |
Why?
| | Polymers | 1 | 1993 | 180 | 0.010 |
Why?
| | Blood Loss, Surgical | 1 | 1990 | 33 | 0.010 |
Why?
| | Liver Cirrhosis | 1 | 1991 | 81 | 0.010 |
Why?
| | Clinical Enzyme Tests | 1 | 1990 | 5 | 0.010 |
Why?
| | Serologic Tests | 1 | 1990 | 14 | 0.010 |
Why?
| | Neoplasms | 1 | 1996 | 599 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1990 | 31 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1992 | 292 | 0.010 |
Why?
| | Health Education | 1 | 1992 | 173 | 0.010 |
Why?
| | Antigens, CD | 1 | 1991 | 292 | 0.010 |
Why?
| | Patient Care Team | 1 | 1992 | 188 | 0.010 |
Why?
| | Incidence | 1 | 1992 | 815 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1991 | 730 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1989 | 87 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1989 | 95 | 0.010 |
Why?
| | Pilot Projects | 1 | 1991 | 497 | 0.010 |
Why?
| | Freeze Drying | 1 | 1988 | 10 | 0.010 |
Why?
| | Self Administration | 1 | 1988 | 35 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 1989 | 190 | 0.010 |
Why?
| | Blood Cells | 1 | 1987 | 24 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 1989 | 540 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1989 | 484 | 0.010 |
Why?
| | Hepatitis delta Antigens | 1 | 1985 | 1 | 0.010 |
Why?
| | Afghanistan | 1 | 1985 | 4 | 0.010 |
Why?
| | Homosexuality | 1 | 1985 | 7 | 0.010 |
Why?
| | Hepatitis B Surface Antigens | 1 | 1985 | 15 | 0.010 |
Why?
| | Retroviridae Infections | 1 | 1985 | 13 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1985 | 66 | 0.010 |
Why?
| | Fibrinogen | 1 | 1985 | 37 | 0.000 |
Why?
| | Hepatitis B virus | 1 | 1984 | 8 | 0.000 |
Why?
| | Molecular Weight | 1 | 1984 | 170 | 0.000 |
Why?
| | Prisoners | 1 | 1985 | 110 | 0.000 |
Why?
| | Cells, Cultured | 1 | 1987 | 1798 | 0.000 |
Why?
| | Peroxides | 1 | 1982 | 7 | 0.000 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1982 | 6 | 0.000 |
Why?
| | Phorbol Esters | 1 | 1982 | 6 | 0.000 |
Why?
| | Neuraminidase | 1 | 1982 | 32 | 0.000 |
Why?
| | Carrier Proteins | 1 | 1982 | 615 | 0.000 |
Why?
|
|
Brettler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|